Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies

Finkelstein, 2003, National medical spending attributable to overweight and obesity: how much, and who’s paying?, Health Aff (Millwood)

Ogden, 2006, Prevalence of overweight and obesity in the United States, 1999–2004, JAMA, 295, 1549, 10.1001/jama.295.13.1549

Bray, 2004, Medical consequences of obesity, J Clin Endocrinol Metab, 89, 2583, 10.1210/jc.2004-0535

Stein, 2004, The epidemic of obesity, J Clin Endocrinol Metab, 89, 2522, 10.1210/jc.2004-0288

Puhl, 2001, Bias, discrimination, and obesity, Obes Res, 9, 788, 10.1038/oby.2001.108

Jolliffe, 2004, Extent of overweight among US children and adolescents from 1971 to 2000, Int J Obes Relat Metab Disord, 28, 4, 10.1038/sj.ijo.0802421

Daniels, 2006, The consequences of childhood overweight and obesity, Future Child, 16, 47, 10.1353/foc.2006.0004

McMahan, 2006, Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis, Pediatrics, 118, 1447, 10.1542/peds.2006-0970

Fontaine, 2003, Years of life lost due to obesity, JAMA, 289, 187, 10.1001/jama.289.2.187

Koba, 2002, Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease, Am Heart J, 144, 1026, 10.1067/mhj.2002.126119

Wilson, 2002, Overweight and obesity as determinants of cardiovascular risk: the Framingham experience, Arch Intern Med, 162, 1867, 10.1001/archinte.162.16.1867

Libby, 2003, Vascular biology of atherosclerosis: overview and state of the art, Am J Cardiol, 91, 3A, 10.1016/S0002-9149(02)03143-0

Trayhurn, 2004, Adipokines: inflammation and the pleiotropic role of white adipose tissue, Br J Nutr, 92, 347, 10.1079/BJN20041213

Dhurandhar, 2001, Infectobesity: obesity of infectious origin, J Nutr, 131, 2794S, 10.1093/jn/131.10.2794S

Schmidt, 2003, Diabesity: an inflammatory metabolic condition, Clin Chem Lab Med, 41, 1120, 10.1515/CCLM.2003.174

Korner, 2003, The emerging science of body weight regulation and its impact on obesity treatment, J Clin Invest, 111, 565, 10.1172/JCI17953

Goldstein, 2004, Adiponectin: a novel adipokine linking adipocytes and vascular function, J Clin Endocrinol Metab, 89, 2563, 10.1210/jc.2004-0518

Vendrell, 2004, Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity, Obes Res, 12, 962, 10.1038/oby.2004.118

Lewis, 2002, Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes, Endocr Rev, 23, 201, 10.1210/edrv.23.2.0461

Golay, 2005, Link between obesity and type 2 diabetes, Best Pract Res Clin Endocrinol Metab, 19, 649, 10.1016/j.beem.2005.07.010

Wassink, 2007, The metabolic syndrome: metabolic changes with vascular consequences, Eur J Clin Invest, 37, 8, 10.1111/j.1365-2362.2007.01755.x

2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486

Lorenzo, 2007, The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes, Diabetes Care, 30, 8, 10.2337/dc06-1414

Misra, 2003, Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots, Nutrition, 19, 457, 10.1016/S0899-9007(02)01003-1

Despres, 2001, Treatment of obesity: need to focus on high risk abdominally obese patients, BMJ, 322, 716, 10.1136/bmj.322.7288.716

National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Heart, Lung and Blood Institute; 2000. Available at: www.nhlbi.nih.gov/guidelines/obesity. Accessed May 10, 2007.

Hofbauer, 2007, The obesity epidemic: current and future pharmacological treatments, Annu Rev Pharmacol Toxicol, 47, 565, 10.1146/annurev.pharmtox.47.120505.105256

Li, 2005, Meta-analysis: pharmacologic treatment of obesity, Ann Intern Med, 142, 532, 10.7326/0003-4819-142-7-200504050-00012

Korner, 2004, Pharmacological approaches to weight reduction: therapeutic targets, J Clin Endocrinol Metab, 89, 2616, 10.1210/jc.2004-0341

Kyrou, 2006, The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome, Ann N Y Acad Sci, 1083, 270, 10.1196/annals.1367.024

Engeli, 2005, Activation of the peripheral endocannabinoid system in human obesity, Diabetes, 54, 2838, 10.2337/diabetes.54.10.2838

Henness, 2006, Rimonabant, Drugs, 66, 2109, 10.2165/00003495-200666160-00006

Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients, Rio-North America: a randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761

Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X

Scheen, 2006, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study, Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8